Hexagon Purus awarded contracts for complete vehicle integration of hydrogen-powered heavy-duty trucks for two North American truck manufacturers
Hexagon Purus has been contracted by two major truck manufacturers in North America to deliver complete vehicle integration of two Hydrogen-powered class 8 trucks. The total sales value is approximately USD 2.2 million (approx. NOK 20 million).
Driving energy transformation
Hexagon Purus will assemble and deliver the complete trucks which involve integration of an electric drivetrain, a fuel cell module as well as the Hexagon Purus ProCabTM Hydrogen Storage system and Hexagon Purus ProPackTM high energy density Li-ion battery packs.
“The momentum for zero emission mobility continues to strengthen. We see growing interest in our fuel cell electric drivetrain technologies, and hydrogen will play an important role in the future of trucking,” says Todd Sloan, EVP Systems, Hexagon Purus. “We are pleased to be selected by major OEMs once again – and to be trusted with complete vehicle integration.”
Timing
The trucks will be delivered starting Q2 2022.
For more information, please contact:
Todd Sloan, EVP Systems, Hexagon Purus
Telephone: +1 250-470-8232 | todd.sloan@hexagonpurus.com
Karen Romer, SVP Communications, Hexagon Composites ASA
Telephone: +47 950 74 950 | karen.romer@hexagongroup.com
About Hexagon Purus ASA:
Hexagon Purus, a Hexagon Composites company, is a world leading provider of hydrogen type 4 high-pressure cylinders, battery packs and vehicle systems integration for fuel cell electric and battery electric vehicles. Hexagon Purus enables zero emission solutions for light, medium and heavy-duty vehicles, buses, ground storage, distribution, maritime, rail and aerospace applications.
Learn more at www.hexagonpurus.com and follow @HexagonPurus on Twitter and LinkedIn.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)19.4.2024 12:10:00 CEST | Press release
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to Humira®The agreement broadens patient access and further commitment to availability of vital biologics in the U.S. and globally Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S. Food and Drug Administration (FDA) approved high-concentration interchangeable biosimilar to Humira. “This new partnership agreement supports our financial guidance and reflects Alvotech’s strong commitment to increasing patient access to more affordable healthcare,” said Robert Wessman, Chairman and CEO of Alvotech. The current multi-product commercialization partnership between T
Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award19.4.2024 12:00:00 CEST | Press release
WASHINGTON, April 19, 2024 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in the National Academy of Sciences building in Washington D.C. Klugman and Madhi received the Sabin Gold Medal, one of the highest recognitions for vaccinologists globally, for their seminal combined contributions to the development of vaccines against pneumonia and diarrheal disease – major causes of death in children in low- and middle-income countries (LMICs). Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute. Apart from pneumonia, their work focused on maternal and children’s vaccines including influenza,
Forløb af ordinær generalforsamling 202419.4.2024 11:59:58 CEST | pressemeddelelse
Investeringsforeningen Investin har i dag afholdt ordinær generalforsamling i henhold til tidligere offentliggjort dagsorden. Ledelsens beretning og årsrapporten for 2023, herunder de i januar 2024 udbetalte udlodninger samt bestyrelsens honorar for 2023 blev godkendt af generalforsamlingen. Alle de af bestyrelsen stillede forslag blev vedtaget, herunder overflytning af afdeling I&T Nordiske Aktier Large Cap og afdeling I&T Globale Aktier ESG Select samt vedtægtsændringer. Til bestyrelsen genvalgtes Kim Høibye, Jesper Lau Hansen, Henrik Vincents Johansen samt Tine Roed, og bestyrelsen konstituerede sig efterfølgende med Kim Høibye som formand. Som revisor for foreningen genvalgtes EY Godkendt Revisionspartnerselskab. Eventuelle henvendelser vedrørende denne meddelelse kan rettes til direktør Tage Fabrin-Brasted på tlf. 44 55 91 60. Med venlig hilsen Investeringsforeningen Investin Tage Fabrin-Brasted Direktør
Investeringsforeningen ValueInvest Danmark – Prospektopdatering19.4.2024 11:32:00 CEST | pressemeddelelse
Opdateret prospekt for Investeringsforeningen ValueInvest Danmark offentliggøres dags dato. Der er foretaget følgende opdateringer i prospektet: Indsættelse af regnskabstal for 2023 Prospektet er vedhæftet denne fondsbørsmeddelelse og kan endvidere downloades på www.valueinvest.dk eller rekvireres ved henvendelse til BI Management A/S, Bredgade 40, 1260 København K, tlf. 77 30 90 00. Med venlig hilsen BI Management A/S Martin Fjordlund Smidt Direktør Vedhæftet fil Prospekt IF ValueInvest Danmark 2024.04.19 FINAL clean inkl. bilag
Forløb af ordinær generalforsamling i Investeringsforeningen ValueInvest Danmark den 19. april 202419.4.2024 11:30:00 CEST | pressemeddelelse
Bestyrelsens beretning Bestyrelsens beretning blev taget til efterretning. Årsrapport, udbytte og bestyrelsesmedlemmernes honorar Årsrapporten for 2023 blev enstemmigt godkendt, herunder bestyrelsens honorar samt forslag om udbetaling af udbytte på 13,60 kr. pr. bevis for andelsklasse A i ValueInvest Global KL, og udbytte på 14,60 kr. pr. bevis for andelsklasse W i ValueInvest Global KL. Udbyttebetalingen til investorerne er foretaget aconto den 5. februar 2024. Forslag fremsat af bestyrelsen Der blev ikke fremsat forslag under dette punkt. Valg til bestyrelsen Bestyrelsen havde indstillet til genvalg af Ole Steffensen, Jens Harck og Bent Erik Carlsen, der enstemmigt blev valgt som medlemmer af bestyrelsen. Valg af revisor EY Godkendt Revisionspartnerselskab blev genvalgt som revisor. Med venlig hilsen Bestyrelsen for Investeringsforeningen ValueInvest Danmark c/o BI Management A/S Bredgade 40 1260 København K